Topics

Articles

Micah Litow, Kalderos’ president and COO, discusses the importance of identifying and resolving noncompliant discount requests, along with addressing the gross-to-net gap for drug manufacturers.

Addressing Revenue Leakage

Recent lawsuits are challenging the constitutionality of provisions in the Inflation Reduction Act.

Industry Slams Medicare Price Negotiation Scheme

Panel explores challenges that could affect their development.

DIA 2023: The Future of Biosimilars, Interchangeables

Session offers a look into the Inflation Reduction Act’s impact on market conditions. 

DIA 2023: The Impact of the IRA

Session explores practicality of models for selling low-cost drugs.

DIA 2023: Solving the Drug Pricing Problem

Pharma company claims that the IRA’s drug pricing clauses violate the First and Fifth Amendments.

Merck Files Lawsuit Against Federal Government

Indicates that reimbursement for new slate of Alzheimer’s treatments will occur only with the completion of studies to support full approval.



Medicare Still Won’t Pay for Alzheimer’s Drugs Without Confirmatory Data

The latest on its implementation—and the implications for biopharma.

IRA Journey Update

The Medicare Part D cap in 2025 won’t solve patients’ need for financial assistance.

Addressing Rx Affordability

New PC column explores commercialization trends and how pharma can adjust to the new squeeze of market, regulatory, pricing, and gross-to-net pressures.

Market Access and Pricing